Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nezam Afdhal

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Hepatology (Baltimore, Md.)|January 15, 2013
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to careChristopher E McGowan, Ali Monis, Bruce R Bacon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical TrialsZobair M Younossi, Maria Stepanova, Mark Sulkowski, et al.
Antiviral Therapy|February 19, 2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialTania M Welzel, K Rajender Reddy, Steven L Flamm, et al.
Plos One|January 6, 2017
Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in WoodchucksManasa Suresh, Kyle E Korolowicz, Maria Balarezo, et al.
The Journal of Infectious Diseases|June 8, 2014
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune responseJennifer C Lin, François Habersetzer, Maribel Rodriguez-Torres, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosisPaul J Pockros, Lennox Jeffers, Nezam Afdhal, et al.
Gastroenterology|August 8, 2006
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Hari S Conjeevaram, Michael W Fried, Lennox J Jeffers, et al.
Hepatology (Baltimore, Md.)|October 9, 2010
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis CThomas J Urban, Alexander J Thompson, Shelton S Bradrick, et al.
Cell Reports|October 27, 2021
Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver diseaseShilpa Tiwari-Heckler, Eric U Yee, Yusuf Yalcin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 28, 2016
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver diseaseZhenghui G Jiang, Elliot B Tapper, Margery A Connelly, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|January 15, 2013
A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to careChristopher E McGowan, Ali Monis, Bruce R Bacon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 23, 2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical TrialsZobair M Younossi, Maria Stepanova, Mark Sulkowski, et al.
Antiviral Therapy|February 19, 2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialTania M Welzel, K Rajender Reddy, Steven L Flamm, et al.
Plos One|January 6, 2017
Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in WoodchucksManasa Suresh, Kyle E Korolowicz, Maria Balarezo, et al.
The Journal of Infectious Diseases|June 8, 2014
Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune responseJennifer C Lin, François Habersetzer, Maribel Rodriguez-Torres, et al.
Hepatology (Baltimore, Md.)|February 28, 2007
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosisPaul J Pockros, Lennox Jeffers, Nezam Afdhal, et al.
Gastroenterology|August 8, 2006
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Hari S Conjeevaram, Michael W Fried, Lennox J Jeffers, et al.
Hepatology (Baltimore, Md.)|October 9, 2010
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis CThomas J Urban, Alexander J Thompson, Shelton S Bradrick, et al.
Cell Reports|October 27, 2021
Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver diseaseShilpa Tiwari-Heckler, Eric U Yee, Yusuf Yalcin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 28, 2016
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver diseaseZhenghui G Jiang, Elliot B Tapper, Margery A Connelly, et al.
Pageof 8